

CSST conclusions  
"Public Consultation on the Place and Use of Textured Breast Implants  
in Aesthetic and Reconstructive Surgery"  
(February 7 and 8, 2019)

The placement of textured breast implants induces a number of known and described risks, among which mammary implant-related large cell anaplastic lymphoma (LAGC-AIM).

As part of reconstructive surgery, the use of textured implants is not essential but is still shown in a number of situations in which the texture of the implant is a proven benefit (in terms of anatomical shape, stability, tissue expansion and reduction of the risk of retractile capsulitis).

In the context of cosmetic surgery, the use of textured implants is not essential but may remain an option among others in a number of situations in which implant texture is a proven benefit (in terms of stability, tissue expansion and risk reduction of the capsulitis retractile).

In the context of the recommendation made by ANSM to preferentially use smooth implants and taking into account the doubts expressed by health professionals, the use of Allergan's Biocell texture should be prohibited. The greatest caution should be reserved for breast implants of equivalent textures and polyurethane implants.

However, the committee does not recommend preventive explantation of these textured implants.

In the context of the recommendation made by the ANSM to use smooth implants preferentially and taking into account the doubts expressed by health professionals about macrot textured implants and polyurethane implants, it is necessary to define limited and controlled conditions of use:

- by a standardized classification of textures to be defined at European level
- by a rigorous and complete information of the patients on these medical devices whose use is not innocuous, on the alternatives that exist to the textured breast implants, on the annual follow-up (at least clinical and ultrasound) to which their pose must give rise
- by a more systematic information of the other health professionals likely to follow patients carrying textured breast implants as for the risks induced by these devices, of which that of LAGC-AIM (a particular attention must be brought to an abundant periprosthetic effusion, redness of the breast, an increase in volume, the perception of a mass or ganglion, an ulceration or the alteration of the general state)

The newly approved National Register of Breast Implants should be launched asap